Published in:
01-12-2020 | ASO Author Reflections
ASO Author Reflections: Tumor Sidedness in CRS/IPC
Authors:
Jonathan B. Yuval, MD, Mohammad Adileh, MD, Andrea Cercek, MD, Garrett M. Nash, MD, MPH
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2020
Login to get access
Excerpt
Patients with peritoneal metastasis of colorectal cancer (pmCRC) have poor prognosis and the regional treatment for this disease, including cytoreductive surgery and intraperitoneal chemotherapy (CRS/IPC), is aggressive and potentially morbid. In recent years, primary tumor location has been found to be an important determinant of response to treatment for locally advanced and metastatic colorectal cancer.
1 Previous reports have demonstrated improved outcomes for left-sided primary tumors in CRS/IPC.
2,
3 However, these studies lacked a uniform treatment protocol and did not investigate the genomic alterations of left- and right-sided tumors. Because proper patient selection is key in the regional treatment of pmCRC, and tumor-sidedness may be an important predictor of response, we wanted to better define the outcomes and tumor mutational profiles of patients with pmCRC in relation to primary tumor site at our institution. …
